Lupin launches generic XenazineLupin is introducing generic Xenazine tablets, which had a market value of $153 million. Glenmark gets FDA nod for generic Finacea gelGlenmark has received the FDA's blessing for generic Finacea gel, which had a market value of about $64.1 million. Armas debuts generic Vidaza Armas Pharmaceuticals is introducing generic Vidaza, which had a market value of about $116 million, the company said. Hikma unveils generic Halcion Hikma is introducing generic Halcion, which had a market value of about $27 million for the year ended September 2018, according to IQVIA data. Glenmark gets FDA's blessing for generic Aubagio Glenmark Pharmaceuticals has received the FDA's OK for generic Aubagio, which had a market value of about $1.6 billion for the year ended September 2018, according to IQVIA. Nexus gets FDA nod for generic Trisenox Nexus is offering a generic version of Teva's Trisenox for intravenous use in leukemia patients. Lupin receives FDA nod for generic Dacogen Lupin has received the FDA's green light for generic Dacogen, which has a market value of about $135.9 million. Cipla gets FDA OK for generic Valcyte The FDA has approved Cipla's generic Valcyte, which had a market value of about $79 million. Lupin receives FDA blessing for generic Pulmicort Lupin has received the FDA's nod for generic Pulmicort, which had a market value of about $474.5 million. Amneal, Lannett complete transition agreement for generic levothyroxine Amneal’s agreement with Lannett accelerates the company's launch of the generic thyroid drug, levothyroxine. First Previous 206 207 208 209 210 Next Last
